Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

RPEP-127812025Nicholls, Stephen J; Pavo, Imre; Bhatt, Deepak L; Buse, John B; Del Prato, Stefano; Kahn, Steven E; Lincoff, A Michael; McGuire, Darren K; Miller, Debra; Nauck, Michael A; Nishiyama, Hiroshi; Nissen, Steven E; Sattar, Naveed; Weerakkody, Govinda; Wiese, Russell J; Zinman, Bernard; Zoungas, Sophia; Basile, Jan; Davies, Melanie J; Giorgino, Francesco; Kellerer, Monika; Ji, Linong; Varkonyi, Tamas; Menon, Venu; Broder, Jonathan C; Herschtal, Alan; D'Alessio, David

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

The New England journal of medicine, 393(24), 2409-2420

View on PubMed ↗Publisher’s paper ↗

Citation

Nicholls, Stephen J; Pavo, Imre; Bhatt, Deepak L; Buse, John B; Del Prato, Stefano; Kahn, Steven E; Lincoff, A Michael; McGuire, Darren K; Miller, Debra; Nauck, Michael A; Nishiyama, Hiroshi; Nissen, Steven E; Sattar, Naveed; Weerakkody, Govinda; Wiese, Russell J; Zinman, Bernard; Zoungas, Sophia; Basile, Jan; Davies, Melanie J; Giorgino, Francesco; Kellerer, Monika; Ji, Linong; Varkonyi, Tamas; Menon, Venu; Broder, Jonathan C; Herschtal, Alan; D'Alessio, David. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.. The New England journal of medicine, 393(24), 2409-2420. https://doi.org/10.1056/NEJMoa2505928